Cibinetide
As of the edition of 20 October 2026, Cibinetide is a protein: stopped in 2017; acts on CSF2RB and EPOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Protein
- Registered trials
- 4, 1 stopped early
- Disease areas
- Blood and lymph; Hormones; Immune system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 2 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Araim Pharmaceuticals | Lead sponsor of trials | 2014 to now |